Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sanofi's Deal With Medco/UBC Seeks Payer Perspective To Inform Drug R&D, Marketing

This article was originally published in The Pink Sheet Daily

Executive Summary

The multi-year, global data, research and consulting agreement will focus primarily on drugs in Phase II or III.

You may also be interested in...

Sanofi/Medco-UBC Evidence Partnership Includes 60 Projects Across Most Therapeutic Categories

Projects include creation of an enhanced “core value dossier” supporting reimbursement for a novel oncology drug and development of a “relative medical value index” framework to help prioritize pipeline projects and highlight opportunities to expand an individual drug study plan to address payer needs.

Comparative Evidence Needs Earlier Consideration In Drug Development Process – Novartis Exec

As comparative effectiveness research grows in importance, drug manufacturers need to factor it, as well as payer evidence needs, into product development decisions, Novartis Head of Comparative Effectiveness Research and Communications Amy Rudolph says.

Pfizer Seeking Medco’s “Real World Data” For Targeted Therapy Development

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts